HN2012001160A - Agonistas mglu2 - Google Patents
Agonistas mglu2Info
- Publication number
- HN2012001160A HN2012001160A HN2012001160A HN2012001160A HN2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A
- Authority
- HN
- Honduras
- Prior art keywords
- mglu2
- mglu2 agonists
- agonists
- aguists
- schizophrenia
- Prior art date
Links
- 101001071429 Homo sapiens Metabotropic glutamate receptor 2 Proteins 0.000 title abstract 2
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION PROVEE AGONISTAS DE MGLU2 NOVEDOSOS UTILES EN EL TRATAMIENTO TRASTORNO BIPOLAR, ESQUIZOFRENIA, DEPRESION, Y TRASTORNO DE ANSIEDAD GENERALIZADA.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382290 | 2009-12-21 | ||
| US30523910P | 2010-02-17 | 2010-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2012001160A true HN2012001160A (es) | 2015-08-24 |
Family
ID=42026702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2012001160A HN2012001160A (es) | 2009-12-21 | 2012-05-30 | Agonistas mglu2 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8318184B2 (es) |
| EP (1) | EP2516406B1 (es) |
| JP (1) | JP5779190B2 (es) |
| KR (1) | KR101395356B1 (es) |
| CN (1) | CN102695701B (es) |
| AR (1) | AR079343A1 (es) |
| AU (1) | AU2010340039B2 (es) |
| BR (1) | BR112012017188B1 (es) |
| CA (1) | CA2784667C (es) |
| CR (1) | CR20120322A (es) |
| CY (1) | CY1114880T1 (es) |
| DK (1) | DK2516406T3 (es) |
| DO (1) | DOP2012000173A (es) |
| EA (1) | EA020229B1 (es) |
| EC (1) | ECSP12011989A (es) |
| ES (1) | ES2435651T3 (es) |
| HN (1) | HN2012001160A (es) |
| HR (1) | HRP20131052T1 (es) |
| IL (1) | IL220011A (es) |
| JO (1) | JO2978B1 (es) |
| MA (1) | MA33824B1 (es) |
| MX (1) | MX2012007332A (es) |
| MY (1) | MY160618A (es) |
| NZ (1) | NZ600305A (es) |
| PE (1) | PE20121688A1 (es) |
| PH (1) | PH12012501253A1 (es) |
| PL (1) | PL2516406T3 (es) |
| PT (1) | PT2516406E (es) |
| RS (1) | RS53063B (es) |
| SG (1) | SG181836A1 (es) |
| SI (1) | SI2516406T1 (es) |
| TN (1) | TN2012000281A1 (es) |
| TW (1) | TWI477490B (es) |
| UA (1) | UA107684C2 (es) |
| WO (1) | WO2011084437A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2790284C (en) | 2010-02-17 | 2019-01-08 | Takeda Pharmaceutical Company Limited | Thieno-pyrimidine compounds having cdc7 inhibitory activity |
| US9056844B2 (en) * | 2010-11-18 | 2015-06-16 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
| AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| SI2721012T1 (sl) * | 2011-06-17 | 2016-08-31 | Eli Lilly And Company | Derivati biciklo(3.1.0)heksan-2,6-dikarboksilne kisline kot agonisti mglu2 receptorja |
| AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| EA033889B1 (ru) * | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5576323A (en) * | 1993-12-03 | 1996-11-19 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| US5688826A (en) | 1995-11-16 | 1997-11-18 | Eli Lilly And Company | Excitatory amino acid derivatives |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| IL156364A0 (en) * | 2001-01-11 | 2004-01-04 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| US7038077B2 (en) * | 2001-01-11 | 2006-05-02 | Eli Lilly And Company | Prodrugs of excitatory amino acids |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| NZ564692A (en) * | 2002-06-11 | 2009-05-31 | Lilly Co Eli | Prodrugs of excitatory amino acids |
| WO2005000790A1 (ja) * | 2003-06-26 | 2005-01-06 | Taisho Pharmaceutical Co., Ltd. | ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体 |
| US9056844B2 (en) * | 2010-11-18 | 2015-06-16 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
| AR083845A1 (es) * | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
-
2010
- 2010-12-09 JO JO2010439A patent/JO2978B1/en active
- 2010-12-09 AR ARP100104553A patent/AR079343A1/es active IP Right Grant
- 2010-12-10 TW TW099143362A patent/TWI477490B/zh active
- 2010-12-15 AU AU2010340039A patent/AU2010340039B2/en active Active
- 2010-12-15 ES ES10798419T patent/ES2435651T3/es active Active
- 2010-12-15 EA EA201290558A patent/EA020229B1/ru not_active IP Right Cessation
- 2010-12-15 RS RS20130530A patent/RS53063B/sr unknown
- 2010-12-15 CA CA2784667A patent/CA2784667C/en active Active
- 2010-12-15 NZ NZ600305A patent/NZ600305A/en unknown
- 2010-12-15 HR HRP20131052AT patent/HRP20131052T1/hr unknown
- 2010-12-15 US US12/968,352 patent/US8318184B2/en active Active
- 2010-12-15 SI SI201030387T patent/SI2516406T1/sl unknown
- 2010-12-15 PL PL10798419T patent/PL2516406T3/pl unknown
- 2010-12-15 MY MYPI2012002794A patent/MY160618A/en unknown
- 2010-12-15 BR BR112012017188-7A patent/BR112012017188B1/pt active IP Right Grant
- 2010-12-15 SG SG2012045563A patent/SG181836A1/en unknown
- 2010-12-15 PE PE2012000856A patent/PE20121688A1/es active IP Right Grant
- 2010-12-15 EP EP10798419.7A patent/EP2516406B1/en active Active
- 2010-12-15 CN CN201080058183.2A patent/CN102695701B/zh active Active
- 2010-12-15 PH PH1/2012/501253A patent/PH12012501253A1/en unknown
- 2010-12-15 UA UAA201206909A patent/UA107684C2/ru unknown
- 2010-12-15 PT PT107984197T patent/PT2516406E/pt unknown
- 2010-12-15 MX MX2012007332A patent/MX2012007332A/es active IP Right Grant
- 2010-12-15 DK DK10798419.7T patent/DK2516406T3/da active
- 2010-12-15 JP JP2012544727A patent/JP5779190B2/ja active Active
- 2010-12-15 WO PCT/US2010/060371 patent/WO2011084437A1/en not_active Ceased
- 2010-12-15 KR KR1020127015935A patent/KR101395356B1/ko active Active
-
2012
- 2012-05-24 IL IL220011A patent/IL220011A/en active IP Right Grant
- 2012-05-30 HN HN2012001160A patent/HN2012001160A/es unknown
- 2012-06-01 TN TNP2012000281A patent/TN2012000281A1/en unknown
- 2012-06-13 CR CR20120322A patent/CR20120322A/es unknown
- 2012-06-14 MA MA34967A patent/MA33824B1/fr unknown
- 2012-06-19 DO DO2012000173A patent/DOP2012000173A/es unknown
- 2012-06-20 EC ECSP12011989 patent/ECSP12011989A/es unknown
-
2013
- 2013-11-14 CY CY20131101012T patent/CY1114880T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2012001160A (es) | Agonistas mglu2 | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| CO6612235A2 (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| ECSP11011541A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
| CR11202S (es) | Botella | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| UY33504A (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma | |
| UY34167A (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
| CR20120362A (es) | Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo | |
| HN2010001614A (es) | Confitura | |
| CR20110202A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| CL2009001363S1 (es) | Pieza para maquina de afeitar. | |
| CR20110550S (es) | Botella | |
| CL2008001837A1 (es) | Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia. | |
| HN2009003469A (es) | Biscocho lleno | |
| HN2011002059A (es) | Tinturas azoicas fibrorreactivas , su preparacion y su uso | |
| EA201391700A1 (ru) | АГОНИСТЫ РЕЦЕПТОРА mGlu2 | |
| CL2011002880S1 (es) | Rodamiento de bola | |
| CL2009001552S1 (es) | Mesa. | |
| CL2009001553S1 (es) | Mesa. | |
| CL2009000054S1 (es) | Frasco para cosmeticos. | |
| CL2009000055S1 (es) | Frasco para cosmeticos. | |
| CR20110546S (es) | Es diseno ornamental de la botella tal y como se muestra y describe en la presente solicitud. | |
| AU316404S (en) | Bodysuit |